Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening severe cutaneous adverse reactions characterized by extensive epidermal detachment and mucosal damage. Although drugs are the primary triggers, viral infections may also contribute to disease development and severity. Recent studies have revealed that necroptosis of epidermal keratinocytes, mediated by the interaction between annexin A1 and formyl peptide receptor 1 (FPR1), plays a critical role in disease progression. However, effective therapeutic strategies targeting this pathway remain limited. Here, we employed a bioluminescent biosensor based on split-luciferase complementation to monitor FPR1-mediated signaling and screen a chemical compound library for potential inhibitors. This approach, combined with cell-based assays, identified chenodeoxycholic acid (CDCA) as a potent inhibitor of FPR1-mediated necroptosis. CDCA significantly suppressed keratinocyte death in vitro and completely prevented SJS/TEN-like symptoms in a humanized mouse model, including severe ocular complications. These findings demonstrate the potential of biosensor-guided drug discovery to identify therapeutic candidates for life-threatening cutaneous adverse reactions. Our study also highlights how innovative molecular sensing technologies can bridge fundamental chemical research and clinical medicine, providing new opportunities for developing effective treatments for severe inflammatory diseases. Reference: H. Kimura et al., Nature Commun., 16, 8708 (2025).